Endometriosis: Novel etiopathogenetic concepts and clinical perspectives

Fertility and Sterility

Volumn 78, Issue 4, 2002, Pages 665-678

  Vignali, Mario ^a   Infantino, Mirco ^b   Matrone, Roberta ^b   Chiodo, Ilda ^b   Somigliana, Edgardo ^b   Busacca, Mauro ^c   Viganò, Paola ^a  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^b Clinica Mangiagalli   (Italy)

^c II Clinica Ostetrico Ginecologica   (Italy)

Author keywords

Antiinflammatory; Aromatase inhibitors; Cancer; Endometriosis; Immunomodulators; Ovarian endometriotic cysts; Raloxifene

Indexed keywords

4 [N (4 BROMOBENZYL) N (1,2,4 TRIAZOL 4 YL)AMINO]BENZONITRILE; ANASTROZOLE; AROMATASE; AROMATASE INHIBITOR; DANAZOL; ESTROGEN; FADROZOLE; GESTAGEN; GONADORELIN ANTAGONIST; GONADORELIN DERIVATIVE; INTERLEUKIN 12; ITURELIX; LETROZOLE; LEUPRORELIN; LEVAMISOLE; LIPOPOLYSACCHARIDE; LOXORIBINE; MEGESTROL ACETATE; MESSENGER RNA; PENTOXIFYLLINE; RALOXIFENE; RECOMBINANT ALPHA2B INTERFERON; SOMATOMEDIN C; TAMOXIFEN; TUMOR NECROSIS FACTOR BINDING PROTEIN;

BREAST CARCINOMA; CANCER RISK; CELLULAR IMMUNITY; CONFERENCE PAPER; DIARRHEA; DISEASE PREDISPOSITION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DYSPNEA; ENDOMETRIOSIS; ESTROGEN SYNTHESIS; GENETIC SUSCEPTIBILITY; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; LABORATORY TEST; LAPAROSCOPY; NAUSEA; NONHUMAN; OVARIECTOMY; OVARY CYST; OVULATION; PATHOGENESIS; POSTMENOPAUSE; PREGNANCY RATE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SIDE EFFECT; VAGINA BLEEDING;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTI-INFLAMMATORY AGENTS; AROMATASE INHIBITORS; ENDOMETRIOSIS; ENZYME INHIBITORS; FEMALE; HUMANS; IMMUNITY, CELLULAR; MEDLINE; OVARIAN CYSTS; OVARIAN DISEASES; OVARIAN NEOPLASMS; POSTMENOPAUSE; RALOXIFENE; RECTAL DISEASES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; VAGINAL DISEASES;

EID: 0036789597     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(02)03233-8     Document Type: Conference Paper

References (94)

1. Marcoux S., Maheux R., Bérubé S. Laparoscopic surgery in infertile women with minimal or mild endometriosis. N Engl J Med. 337:1997;217-222.
2. Sutton C., Ewen S., Whitelow N. Prospective, randomized, double-blind controlled trial of laser laparoscopy in the treatment of pelvic pain associated with minimal, mild, and moderate endometriosis. Fertil Steril. 62:1994;696-700.
3. Sutton C., Pooley A., Ewen S. Follow-up report on a randomized controlled trial of laser laparoscopy in the treatment of pelvic pain associated with minimal to moderate endometriosis. Fertil Steril. 68:1997;1070-1074.
4. Vercellini P., De Giorgi O., Pesole A., Zaina B., Pisacreta A., Crosignani P.G. Prevention of recurrences by postoperative medical treatment. Lemay A., Maheux R., Understanding and managing endometriosis. Advances in research and practice. 1998;261-268 Parthenon Publishing, Quebec City.
5. Vercellini P., Cortesi I., Crosignani P.G. Progestins for symptomatic endometriosis a critical analysis of the evidence . Fertil Steril. 68:1997;393-401.
6. Buzdar A. Role of aromatase inhibitors in advanced breast cancer. Endocr Relat Cancer. 6:1999;219-225.
7. Bulun S.E., Zeitoun K.M., Takayama K., Noble L., Michael D., Simpson E., et al. Aromatase expression in endometriosis biology and clinical perspectives . Lemay A., Maheux R., Understanding and managing endometriosis. Advances in research and practice. 1998;139-148 Parthenon Publishing, Quebec City.
8. Zeitoun K.M., Bulun S.E. Aromatase a key molecule in the pathophysiology of endometriosis and a therapeutic target . Fertil Steril. 72:1999;961-969.
9. Bulun S.E., Zeitoun K.M., Takayama K., Sasano H. Molecular basis for treating endometriosis with aromatase inhibitors. Hum Reprod Update. 6:2000;413-418.
10. Santen R., Harvey H. Use of aromatase inhibitors in breast carcinoma. Endocr Relat Cancer. 6:1999;75-92.
11. Mitwally M.F., Casper R.F. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril. 75:2001;305-309.
12. Kudoh M., Susaki Y., Ideyama Y., Nanya T., Mori M., Shikama H. Inhibitory effects of a novel aromatase inhibitor, YM511, on growth of endometrial explants and insuline-like growth factors-I gene expression in rats with experimental endometriosis. J Steroid Biochem Mol Biol. 63:1997;75-80.
13. Yano S., Ikegami Y., Nakao K. Studies on the effect of the new non-steroidal aromatase inhibitor fadrozole hydrochloride in an endometriosis model in rats. Arzneimittelforschung. 46:1996;192-195.
14. Magtibay P.M., Heppell J., Leslie K.O. Endometriosis-associated invasive adenocarcinoma involving the rectum in a postmenopausal female. Dis Colon Rectum. 44:2001;1530-1533.
15. Buelke-Sam J., Bryant H.U., Francis P.C. The selective estrogen receptor modulator, raloxifene an overview of nonclinical pharmacology and reproductive and developmental testing . Reprod Toxicol. 12:1998;217-221.
16. Dhingra K. Selective estrogen receptor modulation the search for an ideal hormonal therapy for breast cancer . Cancer Invest. 19:2001;649-659.
17. Dutertre M., Smith C.L. Molecular mechanisms of selective estrogen receptor modulator (SERM) action. J Pharmacol Exp Ther. 295:2000;431-437.
18. Katzenellenbogen B.S., Choi I., Delage-Mourroux R., Ediger T.R., Martini P.G., Montano M., et al. Molecular mechanisms of estrogen action selective ligands and receptor pharmacology . J Steroid Biochem Mol Biol. 74:2000;279-285.
19. Fontana A., Delmas D. Clinical use of selective estrogen receptor modulators. Curr Opin Rheumatol. 13:2001;333-339.
20. Baker V.L., Draper M., Paul S., Allerheiligen S., Glant M., Shifren J., Jaffe R.B. Reproductive endocrine and endometrial effects of raloxifene hydrochloride, a selective estrogen receptor modulator, in women with regular menstrual cycles. J Clin Endocrinol Metab. 83:1998;6-13.
21. Grow D.R., Reece M.T. The role of selective oestrogen receptor modulators in the treatment of endometrial bleeding in women using long-acting progestin contraception. Hum Reprod. 15:(Suppl):2000;30-38.
22. Swisher D.K., Tague R.M., Seyler D.E. Effect of the selective estrogen receptor modulator raloxifene on explanted uterine growth in rats. Drug Dev Res. 36:1995;43-45.
23. Fanning P., Kuehl T., Lee R., Pearson S., Wincek T., Pliego J., et al. Video mapping to assess efficacy of an antiestrogen (raloxifene) on spontaneous endometriosis in the rhesus monkey, Macaca mulatta. Kuehl T.J., Bunkley Day Proceedings. 1996;51-61 Texas A&M University Health Science Center, Temple (TX).
24. Braun D.P., Dmowski W.P. Endometriosis abnormal endometrium and dysfunctional immune response . Curr Opin Obstet Gynecol. 10:1998;365-369.
25. Somigliana E., Viganò P., Vignali M. Endometriosis and unexplained recurrent spontaneous abortion pathological states resulting from aberrant modulation of natural killer cell function? Hum Reprod Update. 5:1999;41-52.
26. Semino C., Barrocci S., Semino A., Venturini P.L., Pietra G., Ragni N., et al. Role of major histocompatibility complex class I expression and natural killer-like T cells in the genetic control of endometriosis. Fertil Steril. 64:1995;909-916.
27. De Placido G., Alviggi C., Di Palma G., Carravetta C., Matarese G., Landino G., et al. Serum concentrations of soluble human leukocyte class I antigens and of the soluble intercellular adhesion molecule-1 in endometriosis relationship with stage and non-pigmented peritoneal lesions . Hum Reprod. 13:1998;3206-3210.
28. Somigliana E., Viganò P., Gaffuri B., Guarneri D., Busacca M., Vignali M. Endometrial stromal cells as a source of Intercellular adhesion molecule (ICAM)-1 molecules. Hum Reprod. 11:1996;1190-1194.
29. Viganò P., Gaffuri B., Somigliana E., Busacca M., Di Blasio A.M., Vignali M. Expression of intercellular adhesion molecule (ICAM)-1 mRNA and protein is enhanced in endometriosis versus endometrial stromal cells in culture. Mol Hum Reprod. 4:1998;1150-1156.
30. Garcia-Velasco J.A., Arici A., Zreik T.G., Naftolin F., Mor G. Macrophage derived growth factors modulates Fas ligand expression in cultures endometrial stromal cells a role in endometriosis . Mol Hum Reprod. 5:1999;642-650.
31. Viganò P., Somigliana E., Di Blasio A.M., Cozzolino S., Candiani M., Vignali M. Suppression of natural killer cell function and production of soluble ICAM-1 endometrial stroma versus melanoma . Am J Reprod Immunol. 46:2001;342-348.
32. Kupker W., Schultze-Mosgau A., Diedrich K. Paracrine changes in the peritoneal environment of women with endometriosis. Hum Reprod Update. 4:1998;719-723.
33. Sharpe-Timms K.L. Basic research in endometriosis. Obstet Gynecol Clin Nor Am. 24:1997;269-290.
34. Ho H.N., Wu M.Y., Yang Y.S. Peritoneal cell immunity and endometriosis. Am J Reprod Immunol. 38:1997;400-412.
35. Lebovic D.I., Mueller M., Taylor R.N. Immunobiology of endometriosis. Fertil Steril. 75:2001;1-10.
36. Kobayashi M., Fitz L., Ryan M., Hewick R.M., Clark S.C., Chan S., et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med. 170:1989;827-845.
37. Brunda M.J., Luistro L., Rumennik L., Wright R.B., Wigginton J.M., Wiltrout R.H., et al. IL-12 murine models of a potent antitumor agent . Ann N Y Acad Sci. 795:1996;268-274.
38. Biron C.A. Role of early cytokines, including alpha and beta interferons (IFN-alpha/beta), in innate and adaptive immune responses to viral infections. Semin Immunol. 10:1998;383-390.
39. Goodman M.G., Reitz A.B., Chen R., Bobardt M.D., Goodman J.K., Pope B.L. Selective modulation of elements of the immune system by low molecular weight nucleosides. J Pharmacol Exp Ther. 274:1995;1552-1557.
40. Holcombe R.F., Milovanovic T., Stewart R.M., Brodhag T.M. Investigating the role of immunomodulation for colon cancer prevention results of an in vivo dose escalation trial of levamisole with immunologic endpoints . Cancer Detect Prev. 25:2001;183-191.
41. Namazi M.R. Levamisole a safe and economical weapon against pediculosis . Int J Dermatol. 40:2001;292-293.
42. Somigliana E., Viganò P., Rossi G., Carinelli S., Vignali M., Panina-Bordignon P. Endometrial ability to implant in ectopic sites can be prevented by interleukin-12 in a murine model of endometriosis. Hum Reprod. 14:1999;2944-2950.
43. Ingelmo J.M., Quereda F., Acièn P. Intraperitoneal and subcutaneous treatment of experimental endometriosis with recombinant human interferon-α2b in a murine model. Fertil Steril. 71:1999;907-911.
44. Keenan J.A., Williams-Boyce P.K., Massey P.J., Chen T.T., Caudle M.R., Bukovsky A. Regression of endometrial explants in a rat model of endometriosis treated with the immune modulators loxoribine and levamisole. Fertil Steril. 72:1999;135-141.
45. Ali A.F.M., Fateen B., Ezzet A., Badawy H., Ramadan A., El-tobge A. Laparoscopic intraperitoneal injection of human interferon-α2b in the treatment of pelvic endometriosis a new modality . Obstet Gynecol. 95:(Suppl):2000;478-479.
46. Nothnick W.B. Treating endometriosis as an autoimmune disease. Fertil Steril. 76:2001;223-231.
47. Barbieri R.L. Danazol molecular, endocrine and clinical pharmacology . Prog Clin Biol Res. 323:1990;241-252.
48. Reynolds H. Pentoxifylline - more evidence that it improves host defenses during sepsis. Crit Care Med. 27:1999;681-683.
49. Mandell G.L. Cytokines, phagocytes, and pentoxifylline. J Cardiovasc Pharmacol. 25:(Suppl):1995;20-22.
50. Steinleitner A., Lambert H., Roy S. Immunomodulation with pentoxifylline abrogates macrophage-mediated infertility in an in vivo model a paradigm for a novel approach to the treatment of endometriosis-associated subfertility . Fertil Steril. 55:1991;26-31.
51. Nothnick W.B., Curry T.E., Vernon M.W. Immunomodulation of rat endometriotic implant growth and protein production. Am J Reprod Immunol. 31:1994;151-162.
52. Balasch J., Creus M., Fábregues F., Carmona F., Martínez-Román S., Manau D., et al. Pentoxifylline versus placebo in the treatment of infertility associated with minimal or mild endometriosis a pilot study randomized clinical trial . Hum Reprod. 12:1997;2046-2050.
53. Raza A. Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes. Microsc Res Tech. 50:2000;229-235.
54. D'Antonio M., Martelli F., Peano S., Papoian R., Borrelli F. Ability of recombinant human TNF binding protein-1 (r-hTBP-1) to inhibit the development of experimentally-induced endometriosis in rats. J Reprod Immunol. 48:2000;81-98.
55. D'Hooghe T.M., Cuneo S., Nugent N., Chai D., Deer F., Mwenda J. Recombinant human TNF binding protein-1 (r-hTBP-1) inhibits the development of endometriosis in baboons a prospective, randomized, placebo- and drug-controlled study . Fertil Steril. 76:2001;S1.
56. Meyer R. Uber den staude der frage der adenomyosites adenomyoma in allgemeinen und adenomyometitis sarcomastosa. Zentralblatt fur Gynakologia. 36:1919;745-749.
57. Nisolle M., Donnez J. Peritoneal endometriosis, ovarian endometriosis, and adenomyotic nodules of the rectovaginal septum are three different entities. Fertil Steril. 68:1997;585-595.
58. Hughesdon P.E. The structure of endometrial cysts of the ovary. J Obstet Gynaecol British Empire. 44:1957;69-84.
59. Brosens I.A., Puttemans P.J., Deprest J. The endoscopic localization of endometrial implants in the ovarian chocolate cyst. Fertil Steril. 61:1994;1034-1038.
60. Vercellini P., Aimi G., De Giorgi O., Maddalena S., Carinelli S., Crosignani P.G. Is cystic ovarian endometriosis an asymmetric disease? Br J Obstet Gynaecol. 105:1998;1018-1021.
61. Vercellini P., Pisacreta A., Vicentini S., Stellato G., Pesole A., Crosignani P.G. Lateral distribution of nonendometriotic benign ovarian cysts. Br J Obstet Gynaecol. 107:2000;556-558.
62. Sampson J.A. Perforating haemorrhagic (chocolate) cysts of the ovary. Arch Surg. 3:1921;245-323.
63. Nezhat F., Nezhat C., Allan C.J., Metzger D.A., Sears D.L. Clinical and histologic classification of endometriomas. Implications for a mechanism of pathogenesis. J Reprod Med. 37:1992;771-776.
64. Jain S., Dalton M.E. Chocolate cysts from ovarian follicles. Fertil Steril. 72:1999;852-856.
65. Bahtiyar M.O., Seli E., Oral E., Senturk L.M., Zreik T.G., Arici A. Follicular fluid of women with endometriosis stimulates the proliferation of endometrial stromal cells. Hum Reprod. 13:1998;3492-3495.
66. Somigliana E., Viganò P., La Sala G.B., Balasini M., Candiani M., Incerti L., et al. Follicular fluid as a favourable environment for endometrial and endometriotic cell growth in vitro. Hum Reprod. 16:2001;1076-1080.
67. Cedars M.I. Triphasic oral contraceptives Review and comparison of various regimens . Fertil Steril. 77:2002;1-14.
68. Cohen J. The use of estro-progestatives in the management of endometriosis. Lemay A., Maheux R., Understanding and managing endometriosis. Advances in research and practice. 1998;Parthenon Publishing, Quebec City.
69. Parazzini F., La Vecchia C., Franceschini S., Negri E., Cecchetti G. Risk factors for endometrioid, mucinous and serous benign ovarian cysts. Int J Epidemiol. 18:1989;108-112.
70. Vessey M.P., Villard-Mackintosh L., Painter R. Epidemiology of endometriosis in women attending family planning clinics. Br Med J. 306:1993;182-184.
71. Oral contraceptive use and risk of endometriosis. Italian Endometriosis Group. Br J Obstet Gynaecol. 106:1999;695-699.
72. Vercellini P., Aimi G., Panazza S., Vicentini S., Pisacreta A., Crosignani P.G. Deep endometriosis conundrum evidence in favor of a peritoneal origin . Fertil Steril. 73:2000;1043-1046.
73. Schattman G.L. Endometriosis and pelvic pain the evidence in favor of surgery . Lemay A., Maheux R., Understanding and managing endometriosis. Advances in research and practice. 1998;175-177 Parthenon Publishing, Quebec City.
74. Horowitz I.R., Namnoum A.B., Rock J.A. Recurrent pain following hysterectomy may be due to persistent endometriosis in the utero-sacral ligaments. Lemay A., Maheux R., Understanding and managing endometriosis. Advances in research and practice. 1998;241-244 Parthenon Publishing, Quebec City.
75. Fedele L., Bianchi S., Zanconato G., Portuese A., Raffaelli R. Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis. Fertil Steril. 75:2001;485-488.
76. Jones K.D., Sutton C. Endometriosis an invasive disease . Gynaecol Endosc. 10:2001;79-82.
77. Heaps J.M., Berek J.S. Malignant neoplasms arising in endometriosis. Obstet Gynecol. 75:1990;1023-1028.
78. Vercellini P., Parazzini F., Bolis G., Carinelli S., Dindelli M., Vendola N., et al. Endometriosis and ovarian cancer. Am J Obstet Gynecol. 169:1993;181-182.
79. Brinton L.A., Gridley G., Persson I., Baron J., Bergqvist A. Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol. 176:1997;572-579.
80. Thomas E., Campbell I. Evidence that endometriosis behaves in a malignant manner. Gynecol Obstet Invest. 50:(Suppl 1):2000;2-10.
81. Campbell I., Thomas E. Endometriosis candidate genes . Hum Reprod Update. 7:2001;15-20.
82. Jiang X., Morland S., Hitchcock A., Thomas E., Campbell I. Allelotyping of endometriosis with adjacent ovarian carcinoma reveals evidence of a common lineage. Cancer Res. 58:1998;1707-1712.
83. Erzen M., Rakar S., Klancar B., Syrjanen K. Endometriosis-associated ovarian carcinoma (EAOC) an entity distinct from other ovarian carcinomas as suggested by a nested case-control study . Gynecol Oncol. 83:2001;100-108.
84. Jiang X., Hitchcock A., Bryan E., Watson R., Englefield P., Thomas E., et al. Microsatellite analysis of endometriosis reveals loss of heterozygosity at candidate ovarian tumor suppressor gene loci. Cancer Res. 56:1996;3534-3539.
85. Sato N., Tsunoda H., Nishida M., Morishita Y., Takimoto Y., Kubo T., et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary . Cancer Res. 60:2000;7052-7056.
86. Arvanitis D.A., Goumenou A.G., Matalliotakis I.M., Koumantakis E.E., Spandidos D.A. Low-penetrance genes are associated with increased susceptibility to endometriosis. Fertil Steril. 76:2001;1202-1206.
87. Lafuente A., Molina R., Palou J., Castel T., Moral A., Trias M., et al. Phenotype of glutathione S-transferase Mu (GSTM1) and susceptibility to malignant melanoma. Br J Cancer. 72:1995;324-326.
88. Kanetsky P.A., Holmes R., Walker A., Najarian D., Swoyer J., DuPont G., et al. Interaction of glutathione S-transferase M1 and T1 genotypes and malignant melanoma. Cancer Epidemiol. 10:2001;500-513.
89. Baxter S.W., Thomas E., Campbell I. GSTM1 null polymorphism and susceptibility to endometriosis and ovarian cancer. Carcinogenesis. 22:2001;63-65.
90. Nakayama K., Toki T., Nikaido T., Zahai Y., Konishi I. Genetic alterations in microsatellite marker sites among tumor suppressor genes in endometriosis. Gynecol Obstet Invest. 51:2001;240-242.
91. Hadfield R.M., Manek D.E., Mardon H.J., Barlow D.H., Kennedy S.H. Linkage and association studies of the relationship between endometriosis and genes encoding the detoxification enzymes GSTM1, GSTT1 and CYP1A1. Mol Hum Reprod. 7:2001;1073-1078.
92. Wyshak G., Frisch R.E. Red hair color, melanoma and endometriosis suggestive associations . Int J Dermatol. 39:2000;795-800.
93. Woodworth S.H., Singh M., Yussman M.A., Sanfilippo J.S., Cook C.L., Lincoln S.R. A prospective study on the association between red hair color and endometriosis in infertile patients. Fertil Steril. 64:1995;651-652.
94. Prentice A. Endometriosis. Br Med J. 323:2001;93-95.